Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. ( ABOS ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Alex Braun - VP & Head of Investor Relations Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Business Officer James Doherty - President & Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - BofA Securities, Research Division Thomas Shrader - BTIG, LLC, Research Division Matthew Ryan Tan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and welcome to the Acumen Pharma Third Quarter 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this call may be recorded.
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Alex Braun - VP & Head of Investor Relations Daniel J. O'Connell - CEO & Director Eric Siemers - Chief Medical Officer James Doherty - President & Chief Development Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Jason Eron Zemansky - BofA Securities, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Pete George Stavropoulos - Cantor Fitzgerald & Co., Research Division Trung Chuong Huynh - UBS Investment Bank, Research Division Operator Good day, and welcome to the Acumen Pharmaceuticals Second Quarter 2025 Conference Call and Webcast.
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and CBO Dr. Jim Doherty - President and CDO Dr. Eric Siemers - Chief Medical Officer Conference Call Participants Sarah Medeiros - Cantor Fitzgerald Tom Shrader - BTIG Ting Liu - UBS Operator Good day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Q1 2025 Conference Call and Webcast.
Acumen Pharmaceuticals, Inc. (ABOS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Acumen Pharmaceuticals, Inc. ever had a stock split?
Acumen Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Daniel J. O'Connell CEO | NASDAQ (NGS) Exchange | 00509G209 CUSIP |
| US Country | 61 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for Alzheimer's disease. With a focus on innovation and a pioneering approach to treatment, this company is at the forefront of advancing research and therapy options for one of the most challenging neurodegenerative diseases faced globally. Founded in 1996 and based in Charlottesville, Virginia, Acumen Pharmaceuticals has established itself as a leader in the field, aiming to significantly impact the lives of patients suffering from Alzheimer's disease through groundbreaking treatment solutions.
Products and Services
- Sabirnetug (ACU193)
- Manufacturing and Commercialization Agreement with Lonza Sales AG
- Collaboration and License Agreement with Halozyme, Inc.
A flagship product, sabirnetug (ACU193), represents the core of Acumen Pharmaceuticals’ targeted immunotherapy offerings. It is a recombinant humanized immunoglobulin gamma 2 designed specifically to target soluble amyloid-beta oligomers. Soluble amyloid-beta oligomers are believed to play a critical role in the development and progression of Alzheimer's disease, making ACU193 a significant advancement in targeted therapy. Having completed Phase I clinical trials, sabirnetug is at the forefront of Acumen’s mission to fight Alzheimer's disease.
Acumen Pharmaceuticals has entered into a license agreement with Lonza Sales AG, which encompasses the manufacture and commercialization of sabirnetug. This partnership highlights the company's strategic steps toward ensuring the availability and scalability of this promising therapeutic candidate, emphasizing its commitment to advancing care for Alzheimer's disease patients.
The collaboration with Halozyme, Inc. focuses on the development of a subcutaneous formulation of sabirnetug. This innovative approach aims to improve the delivery and efficacy of the treatment, making it more accessible and potentially more effective for patients. The partnership with Halozyme, Inc. underlines Acumen’s dedication to enhancing Alzheimer's disease treatments through scientific and strategic collaborations.
Contact Information
